Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
布鲁顿酪氨酸激酶抑制剂evobrutinib治疗复发型多发性硬化症3.5年以上的疗效和安全性结果:一项包含脑脊液亚研究的II期随机临床试验的长期随访
期刊:Multiple Sclerosis Journal
影响因子:5
doi:10.1177/13524585241234783
Montalban, Xavier; Piasecka-Stryczynska, Karolina; Kuhle, Jens; Benkert, Pascal; Arnold, Douglas L; Weber, Martin S; Seitzinger, Andrea; Guehring, Hans; Shaw, Jamie; Tomic, Davorka; Hyvert, Yann; Harlow, Danielle E; Dyroff, Martin; Wolinsky, Jerry S